Results from a prospective, multicentre clinical trial published today in the British Journal of Dermatology link to article showed that AI helps significantly improve melanoma detection rates. Dermalyser CEO Christoffer Ekström 228 patients examined in primary care and exhibiting skin lesions raising concern for melanomas. AUROC was 0.960 with maximum sensitivity and specificity of 95.2% and 84.5%, respectively.